Compare RZLT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | KMDA |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.8M | 460.3M |
| IPO Year | 2011 | 2013 |
| Metric | RZLT | KMDA |
|---|---|---|
| Price | $4.47 | $7.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $9.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.3M | 33.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | ★ 26.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $6.50 |
| 52 Week High | $11.46 | $9.35 |
| Indicator | RZLT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 42.20 |
| Support Level | $2.91 | $7.00 |
| Resistance Level | $4.71 | $7.16 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 25.39 | 25.61 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.